Fluvoxamine as an adjunctive agent in schizophrenia

CNS Drug Reviews

Volumn 7, Issue 3, 2001, Pages 283-304

  Silver, Henry ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Sha'ar Menashe MHC   (Israel)

Author keywords

Drug drug interactions; Fluvoxamine; Negative symptoms; Pharmacokinetics; Schizophrenia; Selective serotonin reuptake inhibitor (SSRI)

Indexed keywords

CLOZAPINE; FLUVOXAMINE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

AFFECT; AGGRESSION; CLINICAL TRIAL; COGNITION; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; META ANALYSIS; NAUSEA; OBSESSION; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; SOMNOLENCE; VERTIGO;

EID: 0035669616     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2001.tb00200.x     Document Type: Review

References (202)

1. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale
2. Reliability and validity of a depression rating scale for schizophrenics
3. Depression in people with first-episode schizophrenia
4. A depression rating scale for schizophrenics
5. Fluvoxamine-methadone interaction
6. The negative symptoms assessment: A new instrument to assess negative symptoms of schizophrenia
7. Negative symptoms in schizophrenia: Definition and reliability
8. Positive and negative symptoms in schizophrenia: A critical reappraisal
9. Negative vs. positive schizophrenia: Definition and validation
10. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms
11. Blood clozapine levels elevated by fluvoxamine: Potential for side effects and lower clozapine dosage
12. A longitudinal study of symptom dimensions in schizophrenia: Prediction and patterns of change
13. Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications
14. Open trial of fluvoxamine in the treatment of bulimia nervosa
15. The nature and prevalence of depression in chronic schizophrenic in-patients
16. Serotonin syndrome and fluvoxamine: A case study
17. Depressive symptoms in stable chronic schizophrenia: Prevalence and relationship to psychopathology and treatment
18. Influence of fluvoxamine on tactine metabolism in vitro: Potential implication for the hepatotoxicity in vivo
19. Influence of the CYP1A2 inhibitor fluvoxamine on tactine pharmacokinetics in humans
20. Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
21. Obsessive and compulsive symptoms in chronic schizophrenia
22. Hierarchical diagnosis in chronic schizophrenia: A clinical study of co-occurring syndromes
23. Probable metabolic interaction between methadone and fluvoxamine in addict patients
24. Fluvoxamine in the treatment of compulsive buying
25. Schizophrenia: Lifetime co-morbidity in a community sample
26. Steady state pharmacokinetics of fluvoxamine in young and elderly volunteers
27. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia
28. Olanzapine. Pharmacokinetic and pharmacodynamic profile
29. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYPIA2 activity
30. Treatment of negative symptoms
31. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder
32. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA
33. Pindolol augmentation in aggressive schizophrenic patients: A double-blind cross-over randomized study
34. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors
35. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine
36. Treatment of kleptomania with fluvoxamine
37. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: Two case reports [letter]
38. Review of the animal pharmacology and pharmacokinetics of fluvoxamine
39. Fluvoxamine, a specific beta-hydroxytryptamine uptake inhibitor
40. Depression in schizophrenia: A comparison of three measures
41. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patients
42. Positive and negative schizophrenic symptoms and the role of dopamine
43. Relationship between the Brief Psychiatric Rating Scale and the Scale for Assessment of Negative Symptoms: A study of the correlation and redundancy
44. Co-administration of fluvoxamine increases serum concentrations of haloperidol
45. Fluvoxamine maleate: Disposition in man
46. The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: Increases following fluvoxamine
47. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers
48. Elevated clozapine levels after fluvoxamine initiation
49. Clinical pharmacokinetics of fluvoxamine: Applications to dosage regimen design
50. Fluvoxamine-induced theophylline toxicity
51. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects
52. Fluvoxamine and chlorimipramine in endogenous depression
53. Elevated clozapine plasma concentrations after fluvoxamine initiation
54. Buspirone augmentation of fluvoxamine in the treatment of kleptomania
55. Prescription-event monitoring of 10,401 patients treated with fluvoxamine
56. Enduring negative symptoms in first-episode psychosis: Comparison of six methods using follow-up data
57. Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder
58. Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia
59. The prognostic significance of obsessive-compulsive symptoms in schizophrenia
60. Testing systems for assessment of negative symptoms in schizophrenia
61. A fatal drug interaction between clozapine and fluoxetine
62. Fluvoxamine in prevention of relapse in bulimia nervosa: Effects on eating-specific psychopathology
63. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa
64. Fluvoxamine: An updated review of its use in the management of adults with anxiety disorders
65. Pharmacologic treatment of obsessive-compulsive disorder: Comparative studies
66. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine
67. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia
68. Human cytochromes P450: Problems and prospects
69. Treatment of obsessive-compulsive disorder with fluvoxamine: A multicentre, double-blind, placebo-controlled trial
70. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo
71. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability
72. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions
73. Efficacy of fluvoxamine in obsessive-compulsive disorder: Results of a multicentre double blind, placebo-controlled trial
74. The classification of depressive illness
75. Increased bioavailability of oral melatonin after fluvoxamine coadministration
76. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin
77. Non-linear pharmacokinetics of fluvoxamine and gender differences
78. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial
79. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients
80. Elevated plasma levels of clozapine after concomitant use of fluvoxamine
81. Psychomotor slowing, negative symptoms and dopamine receptor availability - An IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients
82. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes
83. Neurochemical effects of chronic haloperidol and lithium assessed by brain microdialysis in rats
84. Pharmacokinetics of selective serotonin reuptake inhibitors
85. Elevated levels of clozapine in serum after addition of fluvoxamine
86. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight
87. Dysphoric and depressive symptoms in chronic schizophrenia
88. The obsessive-compulsive spectrum disorders
89. Fluvoxamine treatment of body dysmorphic disorder
90. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling
91. Short-term single-blind fluvoxamine treatment of pathological gambling
92. Fluvoxamine in the treatment of binge-eating disorder: A multicenter placebo-controlled, double-blind trial
93. Fluoxetine: A review of its use in anxiety disorders and mixed anxiety and depression
94. Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs)
95. A negative symptom rating scale
96. Further studies on the effects of chronic clozapine on regional extracellular dopamine levels in the brain of conscious rats
97. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
98. A fluvoxamine-caffeine interaction study
99. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide
100. Depot neuroleptics: A comparative review of standard, intermediate, and low dose regimen
101. Plasma concentrations of fluvoxamine and maprotiline in major depression - Implications on therapeutic efficacy and side effects
102. Reliability and validity of the positive and negative syndrome scale for schizoprhenies
103. The schedule for the deficit syndrome: An instrument for research in schizophrenia
104. Fluvoxamine increases the clozapine serum levels significantly
105. Negative symptomatology in schizophrenic outpatients
106. Negative and depressive symptoms in schizophrenia
107. Co-administration of clozapine and fluvoxamine in psychotic patients - Clinical experience
108. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia
109. Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage
110. Movement disorders and abuse potential of the selective serotonin reuptake inhibitors
111. 1A agonist, 8-OH-DPAT, in male rats
112. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
113. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients
114. 3H-paroxetine binding in schizophrenia
115. Costs and benefits of two doses of fluphenazine
116. Fluvoxamine-clozapine dose-dependent interaction
117. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder
118. Clozapine potently stimulates mesocortical dopamine neurons
119. The importance of serotonin-dopamine interactions in the action of clozapine
120. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy
121. Paroxetine binding in aggressive schizophrenic patients
122. The negative component in schizophrenia
123. Negative symptoms in schizophrenia: Considerations for clinical trials. Working group on negative symptoms in schizophrenia
124. A new depression scale designed to be sensitive to change
125. The positive negative dichotomy in schizophrenia
126. Interactions of selective serotonin reuptake inhibition with subtypes of 6 receptors in rat brain
127. Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia
128. Chronic treatment with fluvoxamine, clovoxamine, and placebo: Interaction with digoxin and effects on sleep and alertness
129. Fluvoxamine-Clozapine drug interaction: Inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism
130. Serotonin receptors and animal models of aggressive behavior
131. The brief psychiatric rating scale (BPRS)
132. Fluvoxamine maleate: Metabolism in man
133. Fluvoxamine: An overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders
134. Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment
135. Fluvoxamine treatment of obsessive-compulsive disorder
136. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers
137. Efficacy and safety of fluvoxamine in body dysmorphic disorder
138. Negative and positive symptoms in schizophrenia and depression: A follow-up
139. Psychopharmacology update. Panic disorder: A treatment update
140. Obsessive-compulsive disorder in patients with first-episode schizophrenia
141. Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients
142. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: An add-on open study
143. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro
144. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline
145. Distinguishing change in primary and secondary negative symptoms
146. Obsessive and compulsive symptoms in schizophrenia: A randomized controlled trial with fluvoxamine and neuroleptics
147. Pharmacology of antidepressants - Characteristics of the ideal drug
148. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex
149. Citalopram as an adjuvant in chronic schizophrenia: A double-blind placebo-controlled study
150. Increased trimipramine plasma levels during fluvoxamine comedication
151. The metabolism of psychoactive drugs: A review of enzymatic biotransformation and inhibition
152. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: A placebo-controlled study
153. Melatonin secretion during fluvoxamine treatment in medicated chronic schizophrenic patients: Evidence for the development of tolerance to selective serotonin re-uptake inhibitor
154. The effect of chronic fluvoxamine treatment on overnight melatonin secretion in medicated chronic schizophrenic patients
155. Psychotic symptoms in schizophrenics during chronic fluvoxamine treatment. A report of two cases
156. Fluvoxamine augmentation in clozapine resistant schizophrenia
157. Fluvoxamine augmentation in chronic schizophrenia: An open exploratory study
158. Treatment of aggression in schizophrenia
159. Fluvoxamine augmentation in clozapine resistant schizophrenia. An open pilot study
160. Psychopathological dimensions in schizophrenia
161. Fluvoxamine improves negative symptoms in treated chronic schizophrenia. An add-on double blind placebo controlled study
162. Chronic fluvoxamine treatment reduces platelet MAO activity in medicated schizophrenics
163. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia
164. MAO-A and MAO-B activities in rat striatum, frontal cortex and liver are long-term treatment with fluvoxamine and desipramine
165. A rating scale for extrapyramidal side effects
166. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications
167. Diagnosis of secondary depression in schizophrenia: Implications for DSM-IV
168. Postpsychotic depression and negative symptoms: An investigation of syndromal overlap
169. The use of antidepressants for negative symptoms in a subset of schizophrenic patients
170. Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans
171. "Negative symptoms": Conceptual and methodological problems
172. Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine?
173. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans
174. Non-linear fluvoxamine disposition and relation to some CYP activities
175. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia
176. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients
177. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients
178. Fluvoxamine treatment of trichotillomania
179. 19T magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder
180. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: Drug monitoring and tolerability data from a prospective clinical trial
181. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine
182. Rating scales in research: The case of negative symptoms
183. Toxic effects of theophylline caused by fluvoxamine
184. Overview of the pharmacokinetics of fluvoxamine
185. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose administration
186. Pharmacokinetics of fluvoxamine after intravenous and oral administration
187. "Akinetic depression" in schizophrenia
188. Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin
189. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia
190. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants
191. The oral dose-effect relationship for fluvoxamine: A fixed-dose comparison against placebo in depressed outpatients
192. Fluvoxamine. A review of its safety profile in world-wide studies
193. Implications of normal brain development for the pathogenesis of schizophrenia
194. Prefrontal function in schizophrenia: Confounds and controversies
195. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study
196. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine
197. Endogenous serotonin stimulates striatal dopamine release in conscious rats
198. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex
199. Depressive symptoms in schizophrenia